<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03977753</url>
  </required_header>
  <id_info>
    <org_study_id>LLB-2019-02</org_study_id>
    <nct_id>NCT03977753</nct_id>
  </id_info>
  <brief_title>Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts</brief_title>
  <acronym>EVAsION</acronym>
  <official_title>Study to Evaluate the Efficacy of 2LVERU® JUNIOR and 2LVERU® on the Treatment of Warts.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Labo'Life</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Labo'Life</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human papillomavirus (HPV) infection is very common, as most people will experience infection&#xD;
      during their lifetime. The most common manifestation of HPV infection is common warts. Common&#xD;
      warts may appear at any age.&#xD;
&#xD;
      Conventional treatments can be used to treat warts and they are based on two mechanisms:&#xD;
      stimulation of cellular immunity against HPVs or destruction of the lesion. These treatments&#xD;
      are based on the location of the wart and the degree of the symptoms.&#xD;
&#xD;
      No specific antiviral therapy is available to cure warts and today, there is no treatment&#xD;
      that allows the definitive eradication of the virus.&#xD;
&#xD;
      The 2LVERU® has been available for more than 20 years, and has received a marketing&#xD;
      authorization in Belgium by the Federal Agency for Medicines and Health Products (FAMHP). It&#xD;
      is used as an immune regulator in the treatment of common warts (verruca vulgaris), flat&#xD;
      warts (verruca plana) or plantar warts (verruca plantaris) caused by Human Papillomavirus.&#xD;
      Since 2LVERU® has been made available, clinical observational data collected on treated&#xD;
      patients have shown the beneficial effect on the disappearance of warts.&#xD;
&#xD;
      The purpose of this placebo-controlled, randomized, double-blind trial is the comparison of&#xD;
      the efficacy of the treatment on the disappearance of warts at the end of treatment (6-month&#xD;
      visit) between the 2LVERU® JUNIOR and 2LVERU® versus the placebo group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study duration will be maximum 21 months with 12 months of inclusion and 9 months of&#xD;
      follow-up.&#xD;
&#xD;
      Patients aged 3 years and older who present common warts (Verruca vulgaris), and/or plantar&#xD;
      warts (Verruca plantaris), and/or flat warts (Verruca plana) during a visit with their&#xD;
      dermatologist/general practitioner.&#xD;
&#xD;
      The total number of patients to include will be 374 with 187 patients per group.&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      Comparison of the efficacy of the treatment on the disappearance of warts at the end of&#xD;
      treatment (6-month visit) between the 2LVERU® JUNIOR and 2LVERU® versus the placebo group.&#xD;
&#xD;
      Secondary objectives&#xD;
&#xD;
        -  Comparison of the efficacy of the treatment on the disappearance of warts at 4 months&#xD;
           between groups.&#xD;
&#xD;
        -  Comparison of the efficacy of the treatment on the level of disappearance (4 levels) of&#xD;
           warts at 4 months and 6 months (end of the treatment) between groups&#xD;
&#xD;
        -  Comparison of the efficacy of the treatment on the recurrence of warts 3 months after&#xD;
           the end of treatment between groups&#xD;
&#xD;
        -  Compare the pain related to warts during the study between groups&#xD;
&#xD;
        -  Safety issues.&#xD;
&#xD;
      Treatment phase:&#xD;
&#xD;
        -  Group n°1 = 2LVERU® JUNIOR / 2LVERU® (6 months of treatment)&#xD;
&#xD;
        -  Group n°2 = Placebo (6 months of treatment)&#xD;
&#xD;
      Post-treatment Follow-up phase: 3 months&#xD;
&#xD;
      Treatment will be considered successful if the following three criteria are met for all&#xD;
      treated warts as described at the baseline visit:&#xD;
&#xD;
        -  Normal skin colour at the wart site&#xD;
&#xD;
        -  Normal skin texture at the wart site&#xD;
&#xD;
        -  Normal touch at the wart site Treatment will be considered a failure, at the end of the&#xD;
           treatment, if at least one of the above three criteria is not met for all treated warts&#xD;
           as described at the baseline visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2020</start_date>
  <completion_date type="Anticipated">November 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 16, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Disappearance of warts at the end of treatment (6-month visit)</measure>
    <time_frame>6 months</time_frame>
    <description>A wart will be considered as disappeared if the colour and texture of the skin has returned to normal and can no longer be felt to the touch.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disappearance of warts at 4 months.</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disappearance level (total disappearance, partial disappearance (50%), no modification, increase of number of warts) at 4 months</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Warts recurrence at 9 months</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain evaluation during the study by visual analogic scale and consumption of antalgic medication.</measure>
    <time_frame>6 months</time_frame>
    <description>Minimum value: 0 (better outcome) Maximum Value: 10 (worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: occurence of adverse events (AEs) and severe adverse events (SAEs), considered as related or not to the study drug.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disappearance level (total disappearance, partial disappearance (50%), no modification, increase of number of warts) at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">374</enrollment>
  <condition>Common Wart</condition>
  <condition>Flat Wart</condition>
  <condition>Plantar Wart</condition>
  <arm_group>
    <arm_group_label>2LVERU®/2LVERU® JUNIOR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group N°1: 2LVERU® or 2LVERU® JUNIOR treatment (6 months of treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group N°2: Placebo treatment (6 months of treatment)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2LVERU® or 2LVERU® JUNIOR</intervention_name>
    <description>The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.&#xD;
The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.</description>
    <arm_group_label>2LVERU®/2LVERU® JUNIOR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.&#xD;
The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients, male or female, aged 3 years and older,&#xD;
&#xD;
          -  Patients with common warts (Verruca vulgaris), and/or plantar warts (Verruca&#xD;
             plantaris), and/or flat warts (Verruca plana),&#xD;
&#xD;
          -  Patients (and/or parents if necessary) having the faculties to understand and respect&#xD;
             the constraints of the study,&#xD;
&#xD;
          -  Signature of the Informed Consent Form by the patient (and/or parents if necessary).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have received any curative warts treatment in the previous 2 months prior&#xD;
             to the study,&#xD;
&#xD;
          -  Patients who have received any homeopathic treatment in the previous 2 months prior to&#xD;
             the study,&#xD;
&#xD;
          -  Patients under immunosuppressive treatment,&#xD;
&#xD;
          -  Patients having received immunotherapy or micro-immunotherapy during the last 6&#xD;
             months,&#xD;
&#xD;
          -  Patients with known lactose intolerance,&#xD;
&#xD;
          -  Pregnant or breastfeeding women,&#xD;
&#xD;
          -  Patients who participated in a clinical study in the previous 2-months period,&#xD;
&#xD;
          -  Patients (and/or parents of patients if necessary) who are not sufficiently motivated&#xD;
             to engage on the total study follow-up period, or likely to travel or to move before&#xD;
             the end of the study,&#xD;
&#xD;
          -  Patients with severe immunodeficiency disease requiring long term treatment (*) or&#xD;
             patients under chemotherapy or radiotherapy,&#xD;
&#xD;
          -  Patients under listed homeopathic or phytotherapy treatment (see protocol),&#xD;
&#xD;
          -  Patients addicted to or using recreational drugs,&#xD;
&#xD;
          -  Patient under guardianship and/or curators, (*) important renal or respiratory&#xD;
             insufficiency, transplanted or grafted patients, HIV/AIDS, terminal cancer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>M Yapryntsev</last_name>
    <phone>(0)499 71 79 64</phone>
    <phone_ext>+32</phone_ext>
    <email>mykhaylo.yapryntsev@labolife.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Arlon</city>
        <zip>6700</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Luc (Bouge)</name>
      <address>
        <city>Bouge</city>
        <zip>5004</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey SCHILS, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Audrey SCHILS, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Brussel</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonja CHRISTOFFERSEN, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Sonja CHRISTOFFERSEN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Ecaussinnes-d'enghien</city>
        <zip>7190</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra CORBISIER, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Alexandra CORBISIER, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Fontaine l'Êveque</city>
        <zip>6140</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel SICILIANO, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Michel SICILIANO, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Gozée</city>
        <zip>6534</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Françoise WALRAVENS, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Françoise WALRAVENS, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Juprelle</city>
        <zip>4450</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle PÂQUE, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle PÂQUE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernadette BLOUARD, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Bernadette BLOUARD, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Oisquercq</city>
        <zip>1480</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence TOURNE, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Laurence TOURNE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Plancenoit</city>
        <zip>1380</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laëtitia GOUDETSIDIS, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Laëtitia GOUDETSIDIS, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Quiévrain</city>
        <zip>7380</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Saint-Symphorien</city>
        <zip>7030</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie BEAUCHOT, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Nathalie BEAUCHOT, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Seneffe</city>
        <zip>7180</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristel MESTDAGH, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Kristel MESTDAGH, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Wavre</city>
        <zip>1300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfram FINK, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Wolfram Fink, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

